Easing hot flashes, treating rare genetic diseases and a made-in-Canada vaccine among the year’s notable developments ...
Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we ...
Three start-ups are aiming to create gene-edited babies. Columnist Michael Le Page has no doubt that editing our offspring ...
This stock is a great choice for cautious and aggressive investors.
Stanford scientists have uncovered how mRNA COVID-19 vaccines can very rarely trigger heart inflammation in young men — and ...
A Stanford-led study probes why a very small number of people develop heart inflammation shortly after mRNA COVID-19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback